The CoVID‐TE risk assessment model for venous thromboembolism in hospitalized patients with cancer and COVID‐19
Ang Li(Baylor College of Medicine), Rachel Rosovsky(Harvard University), Rebecca L. Zon(Brigham and Women's Hospital), Imo J. Akpan(Columbia University Irving Medical Center), Devendra Kc(Hartford Hospital), Monica Li(Baylor College of Medicine), Brian I. Rini(Vanderbilt University Medical Center), Petros Grivas(Seattle Cancer Care Alliance), Ziad Bakouny(Dana-Farber Cancer Institute), Julie Fu(Stanford University), Michael A. Thompson(The University of Melbourne), Nicole M. Kuderer, Dimpy P. Shah(The University of Texas MD Anderson Cancer Center), Jeremy L. Warner(Brown University), Clara Hwang(Henry Ford Health System), Daniel G. Stover(Harvard University), Shuchi Gulati(Comprehensive Blood & Cancer Center), Corrie Painter, Rana R. McKay(University of California San Diego), G. Lopes(University of Miami), Sanjay Mishra(Vanderbilt University Medical Center), Amro Elshoury, Jean M. Connors(Harvard University), Yu Shyr(Vanderbilt University), Solange Peters(University Hospital of Lausanne), Jennifer Girard(University of Michigan), Surbhi Shah(WinnMed), Gary H. Lyman(University of Washington), Vaibhav Kumar(University of North Carolina at Chapel Hill), Aakash Desai(University of Connecticut), Balázs Halmos(Montefiore Medical Center), Andrew Schmidt(Dana-Farber Cancer Institute), Pamela Egan(Brown University), Chih‐Yuan Hsu(Vanderbilt University), Amit Kulkarni(University of Minnesota), Jaymin Patel(Beth Israel Deaconess Medical Center), Nathan A. Pennell(Cleveland Clinic)
Cited by 30
Related Papers
Development of tumor mutation burden as an immunotherapy biomarker: utility for the oncology clinic
|Annals of Oncology|2018|2.9k
Alectinib versus Crizotinib in Untreated <i>ALK</i>-Positive Non–Small-Cell Lung Cancer
|New England Journal of Medicine|2017|2.4k
Metastatic non-small cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
|Annals of Oncology|2018|2.3k